Spire Healthcare has announced a new strategic partnership with MAC, a specialist research company. The mutually beneficial agreement will enable MAC to conduct ethically approved clinical trials at Spire hospitals, whilst giving Spire the opportunity to provide associated procedures and services, including MRI, radiology and pathology. It will also further enable consultants at Spire hospitals to partake in clinical trials and assist consultants in carrying out research of their own undertaking.
The relationship, which gives Spire preferred provider status within MAC, has launched at Spire’s Liverpool hospital with several studies having already commenced. Both groups expect to see great benefits from the scheme, as the partnership not only expands capabilities for both Spire and MAC but also provides valuable opportunities for both consultants and patients. Consultants will be able to both contribute to and/or instigate clinical trials, and patients involved in studies will receive enhanced care during the process. In addition, the alliance has extended MAC’s offering to the pharmaceutical sector, and Spire’s extensive facilities have allowed MAC to diversify further into key therapeutic areas that it previously did not have access to.
“As a leading healthcare provider, we are always looking for key ways to facilitate and advance the way in which important research groups such as MAC are able to progress their essential work,” said Chris Chadwick of Spire Healthcare. “We are very excited by the potential benefits for everyone that we hope this strategic partnership will bring. The relationship will open up a number of great research opportunities for our consultants in a supported and structured way. Patients who enrol in trials sponsored by MAC will receive the highest standards of care delivered by experienced and expert specialists. Importantly, all procedures carried out in clinical trials at Spire hospitals will provide a further source of income for each hospital, which will assist in our aim of continuing to invest in state of the art technology, facilities and services in order to deliver exceptional care and commitment for all of our key stakeholders.”
“We are delighted to announce this agreement with Spire Healthcare,” said Mark Dale, Chief Executive Officer of MAC. “We have a long standing relationship with Spire, so we are confident that this new partnership will bring great benefits to all involved. Extending this agreement from Liverpool across the Spire group will give MAC the capacity to deliver larger controlled studies, further enhancing our research capabilities, providing broader opportunities for diversification within different areas for both MAC and Spire. We believe it is a brilliant step forward in the field of clinical research for the UK and I look forward to seeing the partnership progress and develop robustly in the coming months.”
In November 2010, MAC was awarded the SCRIP award for “Best Technical Development in Clinical Trials” for CliniSafe’s Interactive Web-Based Concomitant Medication Management System”. The Company also won the Queen’s Award for Enterprise earlier this year.